| Literature DB >> 27493188 |
Yasushi Ito1, Dimitry Ofengeim1, Ayaz Najafov1, Sudeshna Das2, Shahram Saberi3, Ying Li4, Junichi Hitomi1, Hong Zhu1, Hongbo Chen1, Lior Mayo5, Jiefei Geng1, Palak Amin1, Judy Park DeWitt1, Adnan Kasim Mookhtiar1, Marcus Florez1, Amanda Tomie Ouchida1, Jian-bing Fan6, Manolis Pasparakis7, Michelle A Kelliher8, John Ravits3, Junying Yuan9.
Abstract
Mutations in the optineurin (OPTN) gene have been implicated in both familial and sporadic amyotrophic lateral sclerosis (ALS). However, the role of this protein in the central nervous system (CNS) and how it may contribute to ALS pathology are unclear. Here, we found that optineurin actively suppressed receptor-interacting kinase 1 (RIPK1)-dependent signaling by regulating its turnover. Loss of OPTN led to progressive dysmyelination and axonal degeneration through engagement of necroptotic machinery in the CNS, including RIPK1, RIPK3, and mixed lineage kinase domain-like protein (MLKL). Furthermore, RIPK1- and RIPK3-mediated axonal pathology was commonly observed in SOD1(G93A) transgenic mice and pathological samples from human ALS patients. Thus, RIPK1 and RIPK3 play a critical role in mediating progressive axonal degeneration. Furthermore, inhibiting RIPK1 kinase may provide an axonal protective strategy for the treatment of ALS and other human degenerative diseases characterized by axonal degeneration.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27493188 PMCID: PMC5444917 DOI: 10.1126/science.aaf6803
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728